J&J Completes Firefly Bio Acquisition
Johnson & Johnson completed its $1 billion cash acquisition of Firefly Bio, adding the Firelink degrader antibody conjugate platform for KRAS-driven and other difficult solid tumors. Closing is a meaningful update to the June…
